CMS Open Payments · Program Year 2024
CardioFocus, Inc.
CardioFocus, Inc. reported $1,492,288.05 across General Payments, Research, and Ownership to 202 physicians and teaching hospitals across 226 transactions.
- $1.5M
- All-tracks total
- 226
- Transactions
- 202
- Recipients
- −$264.4K
- General Payments vs PY2023
CardioFocus, Inc. reported $1,492,288.05 across all CMS Open Payments tracks (General + Research + Ownership) to 202 physicians and teaching hospitals in Program Year 2024 - ranking #527 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,248,181.94, averaging $7.4K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer cardiofocus-inc CardioFocus, Inc.
$1.5M · #527/1,925 · 0.0% industry · PY2024
- TOT $1.5M
- RANK #527
- SHARE 0.0%
- TXN 226
- RCP 202
- CAT 5
- GEN $1.2M
- ΔGEN −$264.4K
- TOP1 14.1%
- PY 2024
Volume peers
Nearest volume peer: Cook Research Incorporated ($1.5M)
CardioFocus, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
CardioFocus, Inc.'s CMS-reported General Payments decreased by $264.4K (−17.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: CARDIOFOCUS, INC.PY2023: CARDIOFOCUS, INC.PY2024: CardioFocus, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,512,607.87
- PY2024
- $1,248,181.94
What the Data Shows for CardioFocus, Inc.
Averaging $6.6K per transaction and $7.4K per recipient, CardioFocus, Inc.'s Program Year 2024 total comes to $1,492,288.05 across 226 transactions and 202 physicians and teaching hospitals. In the CMS Open Payments database that is good for rank #527 of 1,925 companies, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.
7 transactions worth $1.1M make "Long-Term Medical Supply or Device Loan" the top general-payment category in the 5-category breakdown below, 90.1% of General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
Across 5 types of general payments, CardioFocus, Inc.'s largest category was "Long-Term Medical Supply or Device Loan" at $1.1M - 90.1% of General Payments.
CardioFocus, Inc. reports 5 general-payment categories - the top three are Long-Term Medical Supply or Device Loan (90.1%), Consulting Fee (7.6%), and Travel and Lodging (1.3%). The remaining 2 categories make up 0.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How CardioFocus, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Long-Term Medical Supply or Device Loan | $1.1M | 7 | 90.1% |
| Consulting Fee | $95.1K | 17 | 7.6% |
| Travel and Lodging | $16.4K | 22 | 1.3% |
| Food and Beverage | $10.2K | 155 | 0.8% |
| Honoraria | $1.5K | 1 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $826,500.00 (66.2%) of $1,248,181.94 in this company's General Payments records across 53 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for CardioFocus, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Westside Regional Medical Center
$176,500.00 across 2 reported transactions
- 2
Osf Heart Of Mary Medical Center
$175,000.00 across 1 reported transactions
- 3
Ucsd Medical Center
$175,000.00 across 1 reported transactions
- 4
Aspirus Wausau Hospital
$150,000.00 across 1 reported transactions
- 5
Abington Memorial Hospital
$150,000.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as CardioFocus, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about CardioFocus, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with CardioFocus, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Adaptive Biotechnologies Corporation
Artivion, Inc.
Servier Pharmaceuticals LLC
Vital Connect, Inc
Cordis US Corp.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.